PMV Pharmaceuticals
PMVP
98 hedge funds and large institutions have $145M invested in PMV Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 29 closing their positions.
833% more call options, than puts
Call options by funds: $541K | Put options by funds: $58K
7% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 30
6% less funds holding
Funds holding: 104 → 98 (-6)
14% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 29
20.31% less ownership
Funds ownership: 111.92% → 91.61% (-20%)
56% less capital invested
Capital invested by funds: $333M → $145M (-$188M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$6.47M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$3.42M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.03M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.99M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$19.4M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$18.4M |
| 3 |
RI
RTW Investments
New York
|
-$14.6M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$5.55M |
| 5 |
TLP
Tri Locum Partners
New York
|
-$5.04M |
PMVP Hedge Fund Activity: Q4 2023 in Review
98 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q4 2023, worth a combined $145M — down 56% from $333M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of PMVP and 25 opened new positions — a net loss of 4 holders — while 30 trimmed existing stakes and 32 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $6.47M. The largest seller was Boxer Capital, exiting entirely with an estimated $19.4M sold.
- 98 institutional investors held PMV Pharmaceuticals (PMVP) as of Q4 2023, down from 104 in Q3 2023.
- Funds reported $145M of PMV Pharmaceuticals stock for Q4 2023, down 56% quarter-over-quarter.
- 25 funds opened new PMV Pharmaceuticals positions in Q4 2023 and 29 closed out, a net change of -4 holders.
- The largest PMV Pharmaceuticals buyer in Q4 2023 was ArrowMark Colorado Holdings, an estimated $6.47M added.
- The largest PMV Pharmaceuticals seller in Q4 2023 was Boxer Capital, an estimated $19.4M sold.
Based on aggregated 13F filings for Q4 2023.